NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

If TLD meet primary endpoint and all other secondary endpoints, and if FDA agree OS as primary endpoint. NWBO doesn't need journal support and can just release TLD any time.

But NWBO went for a journal before data lock and before being unblinded. So it was a strategy call, rather than knowledge about the trial outcome.

The trial outcome came later and hence they convinced Kristyn Power under the guise of an NDA, that proved to her, the trial was good, so she quit her manager job in Deloitte and now manages NWBO Toronto, where she plays Minesweeper inbetween she prepares for the big showdown.